Close Menu

EGFR Biomarkers

News and reporting on EGFR biomarkers.

Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.

The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab. 

The launch of the company's Prism system earlier this month should support the development of an accompanying menu of tests to serve diverse users.

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.

While the guidance may lead to more streamlined CDx indications in precision oncology, test developers will still need to generate evidence, perhaps with limited pharma support.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.

Functional enhancers can accompany oncogenes on the circularized extrachromosomal amplicons found in glioma and other tumors, enhancing cancer growth.

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

As part of the agreement, Kindstar will use InCellDx's single-cell immuno-oncology and oncology diagnostic products in China, including Hong Kong and Macao.

Pages

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.